Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-06-26

Clinical Trial Update: Study of Secukinumab With 2 mL Pre-filled Syringes [Phase 3]

View source ↗

Summary

Phase 3 trial of secukinumab using 2 mL pre-filled syringes in psoriasis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-06-26